More than 1,500 children may have suffered some form of brain development problem or physical disability because their mother took a drug used to treat epilepsy and bipolar disorder during pregnancy, according to the HSE.
The drug Valproate - marketed in Ireland under the brand name Epilim - may be linked to 1,250 children who suffered brain development delay and up to 341 more being born with physical defects, the analysis reveals.
Healthcare experts gathered at a conference in Dublin yesterday to discuss the impact of these conditions, which are known as foetal Valproate syndrome. The European Medicines Agency's pharmacovigilance risk assessment committee last year found that women were not always receiving appropriate and timely information on risks of the drug during pregnancy. It must not be used in pregnancy unless there is no suitable alternative treatment.
The HSE's Rapid Assessment report looked at its potential impact during pregnancy between 1975 and 2015. It suggests that an estimated 43 to 95 children under the age of 16 today will have experienced a major congenital malformation as a result of Valproate exposure and 349 have some form of neurodevelopmental delay.
Dr Colm Henry, HSE chief clinical officer, told the conference: "A specialist paediatric consultant has been appointed to Our Lady's Hospital, Crumlin, to support medical diagnosis, and we are working to improve access to genetic testing and diagnosis.
"We have also supported the development of a diagnostic pathway for Valproate syndrome, we are reviewing how community supports for people affected can be improved, and we have also begun the development of women's health in epilepsy programme."
Professor Amanda Wood, professor of developmental neuropsychology at Aston University, Birmingham, said: "There remain significant gaps in our knowledge about the longer-term outcomes for children exposed in utero to sodium Valproate and we are committed to ensuring that surveillance of neurodevelopmental effects occurs early for new medicines, including anticonvulsants."
Financial Blueprint of a Medical Negligence Case
Medical Negligence and personal injury cases are often a topic of conversation in Ireland. A case is built on the strength of expert reports and testimony. The ancillary costs are driven up by lack of access to salient medical records and details. This further underlines the need for mandatory disclosure and the need for patients to have live access to their own updated medical records.
At Peter McDonnell & Associates we know from experience that the single greatest cause of worry for clients is the issue of legal fees and costs. People worry that before a case commences or at the end of their case, they will be presented with a large legal bill that will be impossible to pay.
Contact us to find out how to fund a High Court Action on 087 2285247 or law@petermcdonnell.ie
*In contentious business, a solicitor may not calculate fees or other charges as a percentage or a proportion of any award or settlement.
Comments